Lauren Shuman

Lauren Shuman

Auto-generated profile, based on publicly available information

Lauren Shuman

Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HLHuili Li
Huili Li
QZQingzhao Zhang
Qingzhao Zhang
LSLauren Shuman
Lauren Shuman
MKMatthew Kaag
Matthew Kaag
JRJay D. Raman
Jay D. Raman
GCGuoli Chen
Guoli Chen
Although advanced bladder cancer overall has a poor prognosis, a subset of patients demonstrate durable response to immune checkpoint inhibitors. Evidence shows that the response to checkpoint inhibitors may be associated with type and degree of immune infiltration in the tumor microenvironment. Here, we evaluated immune markers stratified by molecular subtypes and histologic variants. The study utilized a series of urothelial carcinomas (UCs) by tissue microarray, on which histologic variants and molecular subtypes had previously been established. PD1, CD3, CD8 and CD68 expression was evaluated by immunohistochemistry in tumor infiltrating immune cells, while PD-L1 expression in the tumor microenvironment was assessed. Each marker was scored semi-quantitatively (score 0–3). Tumors were clustered by marker scores using agglomerative methods, and associations among markers, histologies, and molecular subtypes were analyzed. PD-L1 expression in the tumor microenvironment significantly correlated with presence of CD3, CD8 and chronic inflammation. Urothelial carcinoma may be classified as either immune high or low based on marker expression. The immune high group is enriched in higher CD3, PD-L1, and genomically-unstable molecular subtype, suggesting it may respond to checkpoint inhibitors. We also identified a degree of intratumoral heterogeneity in immune markers in bladder cancer.

2 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua I. Warrick
Joshua I. Warrick
WHWenhuo Hu
Wenhuo Hu
HYHironobu Yamashita
Hironobu Yamashita
VWVonn Walter
Vonn Walter
LSLauren Shuman
Lauren Shuman
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed with regions of divergent histomorphology, most commonly squamous differentiation. To define the biologic basis for and clinical significance of this morphologic heterogeneity, here we perform integrated genomic analyses of mixed histology bladder cancers with separable regions of urothelial and squamous differentiation. We find that squamous differentiation is a marker of intratumoral genomic and immunologic heterogeneity in patients with bladder cancer and a biomarker of intrinsic immunotherapy resistance. Phylogenetic analysis confirms that in all cases the urothelial and squamous regions are derived from a common shared precursor. Despite the presence of marked genomic heterogeneity between co-existent urothelial and squamous differentiated regions, no recurrent genomic alteration exclusive to the urothelial or squamous morphologies is identified. Rather, lineage plasticity in bladder cancers with squamous differentiation is associated with loss of expression of FOXA1, GATA3, and PPARG, transcription factors critical for maintenance of urothelial cell identity. Of clinical significance, lineage plasticity and PD-L1 expression is coordinately dysregulated via FOXA1, with patients exhibiting morphologic heterogeneity pre-treatment significantly less likely to respond to immune checkpoint inhibitors.

21 October 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
VOVasty Osei-Amponsa
Vasty Osei-Amponsa
JBJenna M. Buckwalter
Jenna M. Buckwalter
LSLauren Shuman
Lauren Shuman
ZZZongyu Zheng
Zongyu Zheng
HYHironobu Yamashita
Hironobu Yamashita
DDDavid J. DeGraff
David J. DeGraff

26 November 2019 in Oncogenesis
Verified
Journal Article
Open access
PDF file
HYHironobu Yamashita
Hironobu Yamashita
YKYuka I. Kawasawa
Yuka I. Kawasawa
LSLauren Shuman
Lauren Shuman
ZZZongyu Zheng
Zongyu Zheng
TTTruc Tran
Truc Tran
DDDavid J. DeGraff
David J. DeGraff
The discovery of bladder cancer transcriptional subtypes provides an opportunity to identify high risk patients, and tailor disease management. Recent studies suggest tumor heterogeneity contributes to regional differences in molecular subtype within the tumor, as well as during progression and following treatment. Nonetheless, the transcriptional drivers of the aggressive basal-squamous subtype remain unidentified. As PPARɣ has been repeatedly implicated in the luminal subtype of bladder cancer, we hypothesized inactivation of this transcriptional master regulator during progression results in increased expression of basal-squamous specific transcription factors (TFs) which act to drive aggressive behavior. We initiated a pharmacologic and RNA-seq-based screen to identify PPARɣ-repressed, basal-squamous specific TFs. Hierarchical clustering of RNA-seq data following treatment of three human bladder cancer cells with a PPARɣ agonist identified a number of TFs regulated by PPARɣ activation, several of which are implicated in urothelial and squamous differentiation. One PPARɣ-repressed TF implicated in squamous differentiation identified is Transcription Factor Activating Protein 2 alpha (TFAP2A). We show TFAP2A and its paralog TFAP2C are overexpressed in basal-squamous bladder cancer and in squamous areas of cystectomy samples, and that overexpression is associated with increased lymph node metastasis and distant recurrence, respectively. Biochemical analysis confirmed the ability of PPARɣ activation to repress TFAP2A, while PPARɣ antagonist and PPARɣ siRNA knockdown studies indicate the requirement of a functional receptor. In vivo tissue recombination studies show TFAP2A and TFAP2C promote tumor growth in line with the aggressive nature of basal-squamous bladder cancer. Our findings suggest PPARɣ inactivation, as well as TFAP2A and TFAP2C overexpression cooperate with other TFs to promote the basal-squamous transition during tumor progression.

5 August 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
PDF file
LSLauren Shuman
Lauren Shuman
JPJonathan Pham
Jonathan Pham
TWThomas Wildermuth
Thomas Wildermuth
XWXue-ru Wu
Xue-ru Wu
VWVonn Walter
Vonn Walter
DDDavid J. DeGraff
David J. DeGraff

23 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua I. Warrick
Joshua I. Warrick
WHWenhuo Hu
Wenhuo Hu
HYHironobu Yamashita
Hironobu Yamashita
VWVonn Walter
Vonn Walter
LSLauren Shuman
Lauren Shuman
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie